Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF OPERATING OFFICER | April 02, 2026 | April 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date April 02, 2026 · Filed April 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.74 · Expires 2036-04-02 | Direct | 212,241 |
Reported balance
After 2026-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 212,241 · Balance 212,241 F1: The stock option vests with respect to 25% of the underlying shares on April 2, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests with respect to 25% of the underlying shares on April 2, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2026 Filed Apr 6, 2026 20:16 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 212,241 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001999888-26-000002 · form4-04062026_080458.xml · derivative · entry 1 Anastasiou Peter · CIK 0001999888 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,241 Underlying: Common Stock · 212,241 shares Expires 2036-04-02 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on April 2, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:02 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 14,522 | $0.00 Strike: $34.23 | $0.00 |
DisclosureSEC source: 0001415889-25-013401 · form4-05162025_080533.xml · derivative · entry 1 Anastasiou Peter · CIK 0001999888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,522 Underlying: Common Stock · 14,522 shares Expires 2035-05-15 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 15, 2026 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 12:52 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 6,336 | $0.00 Strike: $29.33 | $0.00 |
DisclosureSEC source: 0001415889-24-014964 · form4-05312024_120540.xml · derivative · entry 1 Anastasiou Peter · CIK 0001999888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,336 Underlying: Common Stock · 6,336 shares Expires 2034-05-29 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| November 05, 2023 Filed Nov 8, 2023 14:03 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 6,771 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001415889-23-014880 · form4-11082023_021115.xml · derivative · entry 1 Anastasiou Peter · CIK 0001999888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,771 Underlying: Common Stock · 6,771 shares Expires 2033-11-05 F1 · derivative.exercise_date: The stock option shall vest in 36 equal monthly installments beginning on December 5, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.